Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLQ03 in a wound-healing model for mild to moderate atopic dermatitis
2022-500647-21-00Phase 2Completed
- Sponsor
- Dermaliq Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of DLQ03 in atopic dermatitis (AD) (4 arms), sponsored by Dermaliq Therapeutics, Inc. Primary endpoints: Treatment-emergent adverse events, Concomitant medication use and 4 more. Started Jun 2022; status: completed.
02
Drugs
DLQ03
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-500647-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500647-21-00.